An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following ...
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
High-resolution microultrasonography-guided biopsy was non-inferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer (detection rates, 47.1% and 42.6%, respectively), a ...
Nearly 300 abstracts on prostate cancer research from around the world will be presented at the European Association of Urology Congress (EAU26), taking place in London from 13–16 March 2026.
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Windsong Radiology Group President Dr. Raja Cheruvu became ...
Please provide your email address to receive an email when new articles are posted on . First-line biparametric MRI testing increased the number of biopsies and overdiagnoses vs. first-line PSA ...
Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...
Prostate cancer is one of the leading causes of cancer-related death in men, and some experts project the number of cases to rise over the coming decades. But in a recent Urologic Oncology article, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results